You are here

Article info

Article menu
Download PDFPDF
Commentary
CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?

Authors

  1. Correspondence to Dr Robert Eferl, Medical University Vienna & Comprehensive Cancer Center (CCC), Institute of Cancer Research, Borschkegasse 8a, A-1090 Vienna, Austria; robert.eferl{at}meduniwien.ac.at
View Full Text

Citation

Calvisi D, Eferl R
CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?
Gut 2017;66:1179-1180.

Publication history

  • Received December 9, 2016
  • Accepted December 10, 2016
  • First published January 5, 2017.
Online issue publication 
June 06, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/